Last reviewed · How we verify
BMS-663068
BMS-663068 is an HIV attachment inhibitor that blocks the interaction between HIV and the CD4 receptor on host cells, preventing viral entry.
BMS-663068 is an HIV attachment inhibitor that blocks the interaction between HIV and the CD4 receptor on host cells, preventing viral entry. Used for Treatment-experienced HIV-1 infection in combination with other antiretroviral agents.
At a glance
| Generic name | BMS-663068 |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | HIV attachment inhibitor |
| Target | HIV gp120 envelope protein / CD4 receptor interaction |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
BMS-663068 is a small-molecule fostemsavir prodrug that inhibits HIV attachment to CD4+ T cells by targeting the gp120 envelope protein. It represents a novel class of antiretroviral agents that work at the earliest stage of HIV infection, before the virus can fuse with and enter the host cell. This mechanism is distinct from reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors.
Approved indications
- Treatment-experienced HIV-1 infection in combination with other antiretroviral agents
Common side effects
- Diarrhea
- Nausea
- Headache
- Elevated liver enzymes
Key clinical trials
- Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients (PHASE3)
- Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1 (PHASE2)
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections (PHASE2)
- A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD) (PHASE1)
- Study on Pharmacokinetics (PHASE1)
- A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI) (PHASE1)
- A Open-label, Drug-Drug Interaction With Maraviroc (DDI) (PHASE1)
- Drug-drug Interaction (DDI) Rifabutin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-663068 CI brief — competitive landscape report
- BMS-663068 updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI